S&P 500   4,138.61 (-0.16%)
DOW   32,843.05 (+0.12%)
QQQ   319.95 (-0.56%)
AAPL   164.66 (-0.42%)
MSFT   279.91 (-1.06%)
META   170.91 (+2.27%)
GOOGL   117.20 (-0.23%)
AMZN   138.75 (-1.46%)
TSLA   882.76 (+2.11%)
NVDA   174.11 (-8.31%)
NIO   20.32 (+0.49%)
BABA   90.91 (-1.78%)
AMD   99.73 (-2.52%)
MU   61.61 (-1.36%)
T   18.11 (-1.31%)
CGC   3.16 (+17.04%)
GE   75.71 (+1.82%)
F   16.00 (+4.58%)
DIS   109.38 (+2.58%)
AMC   25.12 (+13.26%)
PYPL   96.30 (+1.03%)
PFE   49.17 (-0.20%)
NFLX   236.60 (+4.33%)
S&P 500   4,138.61 (-0.16%)
DOW   32,843.05 (+0.12%)
QQQ   319.95 (-0.56%)
AAPL   164.66 (-0.42%)
MSFT   279.91 (-1.06%)
META   170.91 (+2.27%)
GOOGL   117.20 (-0.23%)
AMZN   138.75 (-1.46%)
TSLA   882.76 (+2.11%)
NVDA   174.11 (-8.31%)
NIO   20.32 (+0.49%)
BABA   90.91 (-1.78%)
AMD   99.73 (-2.52%)
MU   61.61 (-1.36%)
T   18.11 (-1.31%)
CGC   3.16 (+17.04%)
GE   75.71 (+1.82%)
F   16.00 (+4.58%)
DIS   109.38 (+2.58%)
AMC   25.12 (+13.26%)
PYPL   96.30 (+1.03%)
PFE   49.17 (-0.20%)
NFLX   236.60 (+4.33%)
S&P 500   4,138.61 (-0.16%)
DOW   32,843.05 (+0.12%)
QQQ   319.95 (-0.56%)
AAPL   164.66 (-0.42%)
MSFT   279.91 (-1.06%)
META   170.91 (+2.27%)
GOOGL   117.20 (-0.23%)
AMZN   138.75 (-1.46%)
TSLA   882.76 (+2.11%)
NVDA   174.11 (-8.31%)
NIO   20.32 (+0.49%)
BABA   90.91 (-1.78%)
AMD   99.73 (-2.52%)
MU   61.61 (-1.36%)
T   18.11 (-1.31%)
CGC   3.16 (+17.04%)
GE   75.71 (+1.82%)
F   16.00 (+4.58%)
DIS   109.38 (+2.58%)
AMC   25.12 (+13.26%)
PYPL   96.30 (+1.03%)
PFE   49.17 (-0.20%)
NFLX   236.60 (+4.33%)
S&P 500   4,138.61 (-0.16%)
DOW   32,843.05 (+0.12%)
QQQ   319.95 (-0.56%)
AAPL   164.66 (-0.42%)
MSFT   279.91 (-1.06%)
META   170.91 (+2.27%)
GOOGL   117.20 (-0.23%)
AMZN   138.75 (-1.46%)
TSLA   882.76 (+2.11%)
NVDA   174.11 (-8.31%)
NIO   20.32 (+0.49%)
BABA   90.91 (-1.78%)
AMD   99.73 (-2.52%)
MU   61.61 (-1.36%)
T   18.11 (-1.31%)
CGC   3.16 (+17.04%)
GE   75.71 (+1.82%)
F   16.00 (+4.58%)
DIS   109.38 (+2.58%)
AMC   25.12 (+13.26%)
PYPL   96.30 (+1.03%)
PFE   49.17 (-0.20%)
NFLX   236.60 (+4.33%)
NASDAQ:TTNP

Titan Pharmaceuticals - TTNP Stock Forecast, Price & News

$1.39
-0.07 (-4.79%)
(As of 08/8/2022 10:07 AM ET)
Add
Compare
Today's Range
$1.39
$1.39
50-Day Range
$0.41
$1.46
52-Week Range
$0.35
$2.38
Volume
811 shs
Average Volume
423,636 shs
Market Capitalization
$16.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Titan Pharmaceuticals MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Bearish
6.69% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$897,801 Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.06 out of 5 stars

Medical Sector

1183rd out of 1,293 stocks

Biological Products, Except Diagnostic Industry

185th out of 197 stocks

TTNP stock logo

About Titan Pharmaceuticals (NASDAQ:TTNP) Stock

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in Canada and the European Union. It is also developing kappa opioid agonist peptide program (TP-2021) for use in combination with ProNeura technology for the treatment of chronic pruritus; nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including HIV preventative therapeutic and a contraceptive from a single ProNeura implant for women and adolescent girls. The company was incorporated in 1992 and is based in South San Francisco, California.

Analyst Ratings Changes

A number of brokerages recently issued reports on TTNP. Maxim Group lowered shares of Titan Pharmaceuticals to a "hold" rating in a research report on Thursday, May 26th. StockNews.com initiated coverage on shares of Titan Pharmaceuticals in a research note on Monday, August 1st. They set a "sell" rating on the stock.

Titan Pharmaceuticals Trading Down 4.8 %

NASDAQ:TTNP traded down $0.07 during trading hours on Monday, reaching $1.39. The company's stock had a trading volume of 811 shares, compared to its average volume of 423,636. Titan Pharmaceuticals has a one year low of $0.35 and a one year high of $2.38. The business's 50-day moving average is $0.88 and its 200-day moving average is $0.88.

Insider Buying and Selling at Titan Pharmaceuticals

In related news, major shareholder David E. Lazar acquired 1,165,975 shares of the business's stock in a transaction dated Wednesday, July 6th. The stock was acquired at an average price of $0.77 per share, with a total value of $897,800.75. Following the completion of the transaction, the insider now owns 2,587,108 shares of the company's stock, valued at $1,992,073.16. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 2.70% of the company's stock.

Receive TTNP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Titan Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

TTNP Stock News Headlines

Titan Pharmaceuticals Raises $5.5M Via Equity
Titan Pharmaceuticals to Explore Strategic Alternatives
How to Buy Penny Stocks
See More Headlines
Receive TTNP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Titan Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

TTNP Company Calendar

Last Earnings
3/30/2021
Today
8/08/2022
Next Earnings (Estimated)
8/15/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TTNP
Employees
11
Year Founded
N/A

Profitability

Net Income
$-8,780,000.00
Net Margins
-837.35%
Pretax Margin
-837.35%

Debt

Sales & Book Value

Annual Sales
$1.53 million
Book Value
$0.52 per share

Miscellaneous

Free Float
11,714,000
Market Cap
$16.73 million
Optionable
Optionable
Beta
1.18

Key Executives

  • Dr. Marc Rubin M.D. (Age 67)
    Exec. Chairman & Principal Exec. Officer
    Comp: $390.24k
  • Dr. Katherine L. Beebe-DeVarney Ph.D. (Age 61)
    Pres, COO & Director
    Comp: $383.64k
  • Mr. Brian E. Crowley
    VP of Fin.
  • Mr. Mike Fritz
    National Sales Director
  • Jennifer Kiernan
    Exec. Assistant to CEO & Investor Communications Coordinator
  • Joe Schrei
    Exec. Director of Commercial Operations













TTNP Stock - Frequently Asked Questions

Should I buy or sell Titan Pharmaceuticals stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Titan Pharmaceuticals in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" TTNP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TTNP, but not buy additional shares or sell existing shares.
View TTNP analyst ratings
or view top-rated stocks.

How has Titan Pharmaceuticals' stock performed in 2022?

Titan Pharmaceuticals' stock was trading at $1.02 at the beginning of the year. Since then, TTNP shares have increased by 36.3% and is now trading at $1.39.
View the best growth stocks for 2022 here
.

Are investors shorting Titan Pharmaceuticals?

Titan Pharmaceuticals saw a increase in short interest during the month of July. As of July 15th, there was short interest totaling 641,800 shares, an increase of 77.1% from the June 30th total of 362,300 shares. Based on an average trading volume of 771,300 shares, the days-to-cover ratio is presently 0.8 days. Currently, 6.7% of the company's shares are short sold.
View Titan Pharmaceuticals' Short Interest
.

When is Titan Pharmaceuticals' next earnings date?

Titan Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 15th 2022.
View our TTNP earnings forecast
.

How were Titan Pharmaceuticals' earnings last quarter?

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) announced its earnings results on Tuesday, March, 30th. The specialty pharmaceutical company reported ($0.86) earnings per share for the quarter, beating analysts' consensus estimates of ($1.33) by $0.47. Titan Pharmaceuticals had a negative net margin of 837.35% and a negative trailing twelve-month return on equity of 127.61%.

When did Titan Pharmaceuticals' stock split?

Titan Pharmaceuticals shares reverse split before market open on Tuesday, December 1st 2020. The 1-30 reverse split was announced on Monday, November 30th 2020. The number of shares owned by shareholders was adjusted after the market closes on Monday, November 30th 2020. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of Titan Pharmaceuticals own?

What is Titan Pharmaceuticals' stock symbol?

Titan Pharmaceuticals trades on the NASDAQ under the ticker symbol "TTNP."

How do I buy shares of Titan Pharmaceuticals?

Shares of TTNP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Titan Pharmaceuticals' stock price today?

One share of TTNP stock can currently be purchased for approximately $1.39.

How much money does Titan Pharmaceuticals make?

Titan Pharmaceuticals (NASDAQ:TTNP) has a market capitalization of $16.73 million and generates $1.53 million in revenue each year.

How many employees does Titan Pharmaceuticals have?

Titan Pharmaceuticals employs 11 workers across the globe.

How can I contact Titan Pharmaceuticals?

Titan Pharmaceuticals' mailing address is 400 OYSTER POINT BLVD SUITE 505, SAN FRANCISCO CA, 94080. The official website for the company is www.titanpharm.com. The specialty pharmaceutical company can be reached via phone at (650) 244-4990, via email at skilmer@titanpharm.com, or via fax at 650-244-4956.

This page (NASDAQ:TTNP) was last updated on 8/8/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.